GILEAD AND GALAPAGOS ANNOUNCE TORTUGA PHASE 2 STUDY OF FILGOTINIB IN ANKYLOSING SPONDYLITIS ACHIEVES PRIMARY ...
Foster City, Calif. and Mechelen, Belgium; September 6, 2018; 7.00 CET; Regulated information - Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the randomized, placebo-controlled Phase 2 TORTUGA …